Kimia Biosciences FY26 Results: Profit Drops 22.7% Amid Revenue Decline

Net Profit for FY 2025-26: ₹7.43 crore
Revenue from Operations for FY 2025-26: ₹114.88 crore

Reader Takeaway: Declining revenue and profit highlight performance pressures, while tax disputes add contingent liabilities.

What just happened

Kimia Biosciences Limited has announced its audited standalone financial results for the fiscal year ended March 31, 2026. The company reported a revenue from operations of ₹114.88 crore, a decrease of about 3.4% from ₹118.92 crore in the previous year. Total income also saw a slight dip to ₹116.51 crore from ₹120.24 crore. Most significantly, the net profit for the fiscal year declined by approximately 22.7%, falling to ₹7.43 crore from ₹9.61 crore in the prior year. Consequently, the Earnings Per Share (EPS) decreased to ₹1.64 from ₹2.04.

Why this matters

The decline in both revenue and net profit signals a challenging financial year for Kimia Biosciences. Investors will be watching closely to understand the factors contributing to this contraction and the company's strategy to reverse the trend. The decrease in EPS directly impacts shareholder value. Furthermore, the company redeemed ₹8 crore of preference share capital during the year, indicating a change in its capital structure which could affect future dividend payouts or leverage.

The backstory

Kimia Biosciences operates a DSIR-approved R&D facility in Gurugram and utilizes working capital limits from Kotak Mahindra Bank. The company has faced ongoing legal and tax disputes, including penalties related to Punjab Value Added Tax, Income Tax (AY 2019-20), and TDS across multiple financial years. These contingent liabilities, detailed in Note 37 of the financial statements, represent potential financial drains.

What changes now

While the company achieved an unmodified audit opinion, the statutory auditor highlighted 'Key Audit Matters' concerning revenue recognition complexities and the accounting treatment of R&D expenditure. This suggests that while the accounts are formally clean, areas requiring close scrutiny by management and potentially investors exist. The preference share redemption is a concrete change in the company's financial structure. Investors need to monitor the resolution of tax disputes, which currently stand at ₹0.12 crore for VAT, ₹1.22 crore for Income Tax, and ₹0.015 crore for TDS.

Risks to watch

Key risks for investors include the continuation of the revenue and profit decline, the financial impact of unresolved tax disputes totaling over ₹1.33 crore, and the implications of the auditor's focus on revenue recognition and R&D capitalization policies. The company's reliance on working capital limits also presents a standard operational risk.

Peer comparison

(No peer comparison data available in the filing)

Context metrics (time-bound)

• Working Capital Limits: Sanctioned limits from Kotak Mahindra Bank stood at ₹15.60 crore and ₹14.00 crore as of February 19, 2026.
• Preference Share Redemption: ₹8 crore redeemed during Q1 and Q2 of FY 2025-26.
• Pending Tax Disputes: ₹0.12 crore (VAT), ₹1.22 crore (Income Tax AY 2019-20), ₹0.015 crore (TDS).

What to track next

Investors should closely monitor the company's performance in the upcoming quarters, focusing on revenue growth stabilization, profit margin improvement, and the progress in resolving the ongoing tax and legal disputes. The impact of the preference share redemption on the company's financial leverage and future capital allocation will also be important.